Abstract
Timely administration of appropriate empirical antibiotics in febrile neutropenia is crucial for favourable patient outcomes. There are guidelines in place recommending such antibiotics. However, regional variations and local epidemiological data must be evaluated to tailor the antibiotics for best possible and rational use. In this study, we audited the clinical and microbiological data of febrile neutropenic episodes occurring at a tertiary care haematology institution. Three hundred and ninety-three febrile neutropenic episodes occurring in 123 patients over a 1-year period were analysed for microbial profile, sensitivity and resistance patterns, and finally clinical outcomes. Gram-negative bacilli (GNB) blood stream infections (46.9%) were more prevalent as compared to gram-positive infections (41.9%). Overall mortality due to complicated neutropenic sepsis was 19.5% (24/123 patients). Increased resistance to carbapenems, beta-lactam beta-lactamase inhibitor combinations, aminoglycosides, fluoroquinolones, and cephalosporins were observed. Cefepime and tigecycline resistance were seen in 20% and 15% GNB isolates, respectively. Chest was the most frequent focus of infection, and acute myeloid leukaemia (AML) was the most common underlying disorder which correlated with the likelihood of death (p < 0.01). Multidrug-resistant GNB (esp. Klebsiella sp.) are still most worrisome isolates in neutropenic patients. Single-agent cefepime or piperacillin-tazobactam/tigecycline combination may be considered empirical agents. Chest infections and AML were independent predictors of poor clinical outcome in neutropenic patients. Regular audit of infections and antibiotic susceptibility data is needed to improve clinical outcomes in patients with febrile neutropenia.
Similar content being viewed by others
Data availability
Data are available for publication/review.
References
Centers for Disease Control and Prevention (2020) Bloodstream infection event (Central line-associated bloodstream infection and non-central line associated bloodstream infection). Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf
Lakshmaiah KC, Malabagi AS, Govindbabu, Shetty R, Sinha M, Jayashree RS (2015) Febrile neutropenia in hematological malignancies: clinical and microbiological profile and outcome in high risk patients. J Lab Physicians 7(2):116–120. https://doi.org/10.4103/0974-2727.163126
Hosiriluck N, Klomjit S, Rassameehiran S, Sutamtewagul G, Tijani L, Radhi S (2015) Prognostic factors for mortality with febrile neutropenia in hospitalized patients. Chronicles. [cited 2020Oct.12] 3(9):3-13. Available from: https://pulmonarychronicles.com/index.php/pulmonarychronicles/article/view/188
Mandal PK, Maji SK, Dolai TK, De R, Dutta S, Saha S, Bhattacharyya M (2015) Micro-organisms associated with febrile neutropenia in patients with haematological malignancies in a tertiary care hospital in Eastern India. Indian J Hematol Blood Transfus 31(1):46–50. https://doi.org/10.1007/s12288-014-0393-1
Wingard JR Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients ( high-risk patients ). Uptodate. Available from: https://www.uptodate.com/contents/treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA (2011) Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52(4):e56–e93. https://doi.org/10.1093/cid/cir073
Chotiprasitsakul D, Srichatrapimuk S, Kirdlarp S, Pyden AD, Santanirand P (2019) Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital. Infect Drug Resist 12:461–468. https://doi.org/10.2147/IDR.S192540
Al-Tawfiq Jaffar A, Kareem H, Hanan K, Bassam S, Suhail A, Madeeha N, Raza Safia AA (2019) Epidemiology and source of infection in patients with febrile neutropenia: a ten-year longitudinal study. J Infect Public Health 12:364–366
Rolston KVI (2005) Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40(Supplement_4):S246–S252. https://doi.org/10.1086/427331
Sepkowitz KA (2005) Treatment of patients with hematologic neoplasm, fever, and neutropenia. Clin Infect Dis 40(Suppl 4):S253–S256. https://doi.org/10.1086/427330
Bhattacharya S, Goel G, Mukherjee S, Bhaumik J, Chandy M (2015) Epidemiology of antimicrobial resistance in an oncology center in eastern India. Infect Control Hosp Epidemiol 36(7):864–866. https://doi.org/10.1017/ice.2015.96
Goel G, Hmar L, Sarkar De M, Bhattacharya S, Chandy M (2014) Colistin-resistant Klebsiella pneumoniae: report of a cluster of 24 cases from a new oncology center in eastern India. Infect Control Hosp Epidemiol 35(8):1076–1077. https://doi.org/10.1086/677170
Agyare C, Etsiapa Boamah V, Ngofi Zumbi C, Boateng OF (2019) Antibiotic use in poultry production and its effects on bacterial resistance. In: Antimicrobial resistance-a global threat
Guarana M, Nucci M, Nouér SA (2019) Shock and early death in hematologic patients with febrile neutropenia. Antimicrob Agents Chemother 63(11):e01250–e01219. https://doi.org/10.1128/AAC.01250-19
Micozzi A, Gentile G, Minotti C, Cartoni C, Capria S, Ballarò D, Santilli S, Pacetti E, Grammatico S, Bucaneve G, Foà R (2017) Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis 17(1):203. https://doi.org/10.1186/s12879-017-2297-9
Zhang Y, Guo LY, Song WQ et al (2018) Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis 18(1):248. https://doi.org/10.1186/s12879-018-3160-3
Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, Gyssens IC, Kern WV, Klyasova G, Marchetti O, Engelhard D, Akova M, ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98(12):1826–1835. https://doi.org/10.3324/haematol.2013.091025 Erratum in: Haematologica. 2014 Feb;99(2):400
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(suppl 5):v111–v118. https://doi.org/10.1093/annonc/mdw325
Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792. https://doi.org/10.1007/s00277-017-3098-3
Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, Ruhnke M, Penack O, Salwender H, Wolf HH, Christopeit M, Neumann S, Maschmeyer G, Karthaus M, Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (2014) Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol 25(5):936–947. https://doi.org/10.1093/annonc/mdt545
Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D, Cardoso F, ESMO Guidelines Committee (2015) Central venous access in oncology: ESMO Clinical Practice Guidelines. Ann Oncol 26 Suppl 5:v152–v168. https://doi.org/10.1093/annonc/mdv296
Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, Shimono N, Akashi K (2013) Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity. PLoS One 8(1):e54190. https://doi.org/10.1371/journal.pone.0054190
Kim PW, Wu YT, Cooper C, Rochester G, Valappil T, Wang Y, Kornegay C, Nambiar S (2010) Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 51(4):381–389. https://doi.org/10.1086/655131
Yahav D, Paul M, Fraser A, Sarid N, Leibovici L (2007) Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7(5):338–348. https://doi.org/10.1016/S1473-3099(07)70109-3
Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P, Specchia G, Fanci R, Luppi M, Cudillo L, Cantaffa R, Milone G, Bocchia M, Martinelli G, Offidani M, Chierichini A, Fabbiano F, Quarta G, Primon V, Martino B, Manna A, Zuffa E, Ferrari A, Gentile G, Foà R, Del Favero A (2014) Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol 32(14):1463–1471. https://doi.org/10.1200/JCO.2013.51.6963
Verlinden A, Mikulska M, Knelange NS, Averbuch D, Styczynski J, Infectious Diseases Working Party (IDWP) of the European Group for Blood and Marrow Transplantation Group (EBMT) (2020) Current antimicrobial practice in febrile neutropenia across Europe and Asia: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant 55(8):1588–1594. https://doi.org/10.1038/s41409-020-0811-y
Khan ZA, Siddiqui MF, Park S (2019) Current and emerging methods of antibiotic susceptibility testing. Diagnostics (Basel) 9(2):49. https://doi.org/10.3390/diagnostics9020049
Author information
Authors and Affiliations
Contributions
Shouriyo Ghosh: concept, clinical data curation, statistics, manuscript drafting, editing, and analysis
Mandira Chakraborty: microbiological data collection, archiving, analysis
Sambit Samanta: clinical management, decision-making, concept
Nilanjan Sinha: clinical management, decision-making
Sandeep Saha: clinical management, decision-making
Arnab Chattopadhyay: clinical management, decision-making
Siddhartha Sankar Roy: clinical management, decision-making
Maitreyee Bhattacharyya: concept, manuscript editing, analysis, overall supervision
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval
The study was approved by the Institutional Ethical Committee, Medical College Hospital, Kolkata.
Consent to participate
Informed consent was taken from patients.
Consent for publication
Yes
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mandira Chakraborty is a co-first author
Rights and permissions
About this article
Cite this article
Ghosh, S., Chakraborty, M., Samanta, S. et al. Analysis of blood stream infections, antibiograms and clinical outcomes in haematological patients with febrile neutropenia: data from a tertiary care haematology institute in India. Ann Hematol 100, 395–403 (2021). https://doi.org/10.1007/s00277-020-04324-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-04324-8